The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 23, 2020
Filed:
Jul. 31, 2015
Applicant:
Nuevolution A/s, Copenhagen, DK;
Inventors:
Sanne Schrøder Glad, Ballerup, DK;
Kim Birkebæk Jensen, Rødovre, DK;
Niels Grøn Nørager, Copenhagen, DK;
Ian Sarvary, Kristinehamn, SE;
Mikkel Vestergaard, Greve, DK;
Alex Haahr Gouliaev, Veksø Sjælland, DK;
Lene Teuber, Værløse, DK;
Luigi Piero Stasi, Søllerød, DK;
Assignee:
NUEVOLUTION A/S, Copenhagen, DK;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); C07D 401/12 (2006.01); C07D 487/04 (2006.01); C07D 403/12 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 403/04 (2006.01); C07D 403/14 (2006.01); C07D 405/12 (2006.01); C07D 239/48 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01); C07D 411/12 (2006.01); C07D 413/04 (2006.01); C07D 417/14 (2006.01); C07D 451/04 (2006.01); C07D 471/10 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 401/04 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); C07D 239/48 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 411/12 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 451/04 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01);
Abstract
Disclosed are compounds of Formula I, which are active toward nuclear receptors such as nuclear retinoic acid receptor-related orphan receptors (RORs), pharmaceutical compositions containing the compounds of Formula I, and methods of treating inflammatory, metabolic, oncologic and autoimmune diseases or disorders using the of the compounds Formula I in therapy.